★ ANNUAL REVIEW 2027 SPONSORSHIPS NOW OPEN   Learn more →

Log In  |  Become a Member  |  Sponsor  |  ⌕ Search

News/Compliance & Enforcement/DOJ Defends Viability of Fraud-on-the-FDA Theory in Statement of Interest
Free SampleYou’re reading a free sample of the Compliance & Enforcement Brief. Members get every case digest like this, six days a week.See Membership Options
Expert Opinion·Compliance & Enforcement Brief

DOJ Defends Viability of Fraud-on-the-FDA Theory in Statement of Interest

Over the past decade, relators have attempted to expand the long-established “fraudulent inducement” theory of liability into a novel “fraud-on-the-FDA” theory. The fraudulent inducement theory posits that when a defendant’s fraudulent conduct induces a government entity to enter into a contract with the defendant, the claims for payment submitted under that contract are false. However, the fraud-on-the-FDA theory stretches this causal chain by contending that fraudulent conduct directed at FDA can render false the claims for payment submitted to an entirely different government entity, such as CMS. Courts have been divided as to the viability of this theory.

Source:

Not ready to join? Take the free Pub K Weekly digest.One email. Free. Top industry articles, the community calendar, and the latest job postings.